{
    "id": "wrong_mix_range_subsidiary_00036_1",
    "rank": 81,
    "data": {
        "url": "https://www.linkedin.com/posts/johnqleonard_drugdiscovery-ai-bionformatics-activity-7198801285641330689-eKzv",
        "read_more_link": "",
        "language": "en",
        "title": "John Leonard on LinkedIn: #drugdiscovery #ai #bionformatics",
        "top_image": "https://media.licdn.com/dms/image/D4D22AQE9T6TWRMGeJg/feedshare-shrink_800/0/1716327972425?e=2147483647&v=beta&t=TX6pMBaQ5vVcxkpnuTb0ng5cAVOEF9q44pR6waXQCbk",
        "meta_img": "https://media.licdn.com/dms/image/D4D22AQE9T6TWRMGeJg/feedshare-shrink_800/0/1716327972425?e=2147483647&v=beta&t=TX6pMBaQ5vVcxkpnuTb0ng5cAVOEF9q44pR6waXQCbk",
        "images": [
            "https://media.licdn.com/dms/image/C5616AQHLloJE4AhI3A/profile-displaybackgroundimage-shrink_200_800/0/1517732919123?e=2147483647&v=beta&t=K4xQF_8QwBJhDBJwjnTLt6D_308RRWZyCzIcVKh1vHA"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "John Leonard"
        ],
        "publish_date": "2024-05-21T21:46:13.715000+00:00",
        "summary": "",
        "meta_description": "This morning I facilitated an energetic panel discussion between biotech founders, big pharma leaders and academics about how AI, machine learning, and…",
        "meta_lang": "en",
        "meta_favicon": "https://static.licdn.com/aero-v1/sc/h/al2o9zrvru7aqj8e1x2rzsrca",
        "meta_site_name": "",
        "canonical_link": "https://www.linkedin.com/posts/johnqleonard_drugdiscovery-ai-bionformatics-activity-7198801285641330689-eKzv",
        "text": "Last night the world witnessed a monumental moment as Dr. Katalin Karikó accepted the prestigious Neirenberg Prize. Kati’s groundbreaking work in mRNA therapeutics has not only earned her this esteemed award but also the Nobel Prize in 2023. Kati's story is a beacon of inspiration. Her relentless dedication and pioneering discoveries have paved the way for the modified mRNA technology used in COVID-19 vaccines by Pfizer-BioNTech and Moderna, marking a turning point in global health, vaccine development and a paradigm shift in therapeutics. In addition to being a scientific luminary, Kati is genuinely kind, funny and wonderful to be around. Kati's journey marked by perseverance through challenges and skepticism, reminds us all of the power of steadfast commitment to science and innovation. I highly recommend her autobiographical book “Breaking Through” that exemplifies how passion fueled by purpose can lead to revolutionary breakthroughs that benefit humanity. Congratulations, Dr. Katalin Karikó, on your Neirenberg Prize. Your legacy is a testament to the indomitable spirit of scientific exploration and its capacity to change lives. Here’s to many more years of innovation, discovery, and inspiring the next generation of scientists. #ScienceHeroes #mRNATechnology #NeirenbergPrize #NobelPrize2023 #Innovation #GlobalHealth #mRNA\n\nI'm thrilled to share an insightful article on the future of biotech and AI-driven drug discovery, \"Is AI-driven drug discovery really the future of biotech? Part II.\" It's a must-read for anyone in the space, and I'm proud to have been featured in an interview. This piece explores the transformative power of AI in biopharma, diving deep into its role in drug development, its diverse applications, and the challenges it's poised to overcome. The article provides valuable insights from industry experts, shedding light on the path AI is paving for the future of healthcare. As someone deeply passionate about the intersection of biotech and AI, it was an honor to contribute to this conversation. I believe that AI is not just a buzzword; it's a game-changer that has the potential to revolutionize the industry and improve patient outcomes. Let's stay informed and inspired as we embark on this incredible journey at the crossroads of science and technology. Feel free to share your thoughts and insights—I'd love to hear your perspective on this exciting topic! #Biotech #AI #DrugDiscovery #Innovation #FutureOfHealthcare #LeadingEdgeBio #ProtaBody\n\nA Special Protocol Assessment (SPA) is a process provided by the US Food and Drug Administration (FDA) that allows sponsors to obtain FDA agreement on the design and analysis of a clinical trial before the trial begins. The SPA process involves submitting a protocol for a planned clinical trial to the FDA and receiving written feedback from the agency on whether the proposed study design, clinical endpoints, and statistical analysis plan are acceptable for FDA approval. This agreement provides a clear path for drug development and allows sponsors to design their clinical trial with the confidence that the FDA will accept the trial design, thus reducing the risk of failure and the need for additional trials. Advantages of obtaining a SPA from the FDA include: 1. Regulatory certainty: SPA provides the sponsor with regulatory certainty and a clear understanding of FDA expectations, which helps to minimize the risk of failure due to study design issues. 2. Time and cost savings: SPA can help to avoid costly and time-consuming changes to study design, protocol, and statistical analysis plan later in the clinical trial process, thus saving time and money. 3. Enhanced credibility: SPA enhances the credibility of the clinical trial results and can provide additional support for regulatory approval. 5. Improved communication: SPA promotes better communication and collaboration between the sponsor and the FDA, which can help to facilitate the regulatory review process. 6. Tax Benefits: Last, but not least, a SPA provides additional support for certain R&D expenses for tax deductions. For example, with an FDA-granted SPA, there is potential to demonstrate to the IRS that the expenses incurred during the trial are directly related to the development of the drug or biologic and therefore eligible for tax deductions. Targazyme's lead phase 3 registration-ready TZ101 has been granted a SPA by the FDA indicating htat we are designing clinical trials that are more likely to meet FDA regulatory requirements and ultimately gain approval for their drug or medical product. #clinicaltrials #fda #drugdevelopment #Targazyme"
    }
}